 |
|
Epidemiologic Changes in Bacteremic Pneumococcal Disease in Patients With Human Immunodeficiency Virus in the Era of Highly Active Antiretroviral Therapy
Imma Grau, MD;
Roman Pallares, MD;
Fe Tubau, MD;
Marco H. Schulze, MD;
Ferran Llopis, MD;
Daniel Podzamczer, MD;
Josefina Liñares, MD;
Francesc Gudiol, MD; for the Spanish Pneumococcal Infection Study Network (G03/103)
Arch Intern Med. 2005;165:1533-1540.
Background The use of highly active antiretroviral therapy (HAART) may change the incidence of, and the risk and prognostic factors for, invasive pneumococcal disease in patients with human immunodeficiency virus (HIV).
Methods We prospectively studied 142 episodes of pneumococcal bacteremia in 122 HIV-infected adults. Eighty-five episodes occurred in the pre-HAART era (1986-1996) and 57 in the HAART era (1997-2002). A case-control study was conducted to identify risk factors for pneumococcal bacteremia in the HAART era.
Results The incidence of pneumococcal bacteremia dropped from 24.1 episodes per 1000 patient-years in the pre-HAART era to 8.2 episodes per 1000 patient-years in the HAART era (P = .01). Compared with patients in the pre-HAART era, patients in the HAART era had more associated comorbidity (42% vs 26%; P = .04), fewer recurrences of bacteremia (4% vs 15%; P = .04), and a higher 30-day mortality rate (26% vs 8%; P=.004). High antibiotic resistance rates were observed in both periods. By multivariate analysis, the major risk factors for pneumococcal bacteremia in the HAART era were associated comorbidity (adjusted odds ratio [OR], 3.36), alcohol abuse (adjusted OR, 5.28), prior hospitalization (adjusted OR, 3.38), current smoking (adjusted OR, 5.19), and CD4 cell count lower than 100 cells/µL (adjusted OR, 2.38); while use of HAART (adjusted OR, 0.37) and pneumococcal vaccine (adjusted OR, 0.39) were protective factors.
Conclusions The widespread use of HAART and pneumococcal vaccine may decrease the incidence of invasive pneumococcal disease in HIV-infected patients. Risk factors and prognosis of pneumococcal bacteremia in the HAART era are more similar to those reported in non–HIV-infected individuals.
Author Affiliations: Infectious Disease Service (Drs Grau, Pallares, Llopis, Podzamczer, and Gudiol), Clinical Research Unit (Drs Grau, Pallares, and Llopis), and Microbiology Service (Drs Tubau and Liñares), IDIBELL–Hospital de Bellvitge and University of Barcelona, Barcelona, Spain; and Klinik für Innere Medizin, Klinikum St Georg, Lehrkrankenhaus der Universität Leipzig, Leipzig, Germany (Dr Schulze).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Cross-Sectional Study of Nasopharyngeal Carriage of Streptococcus pneumoniae in Human Immunodeficiency Virus-Infected Adults in the Conjugate Vaccine Era
Onwubiko et al.
J. Clin. Microbiol. 2008;46:3621-3625.
ABSTRACT
| FULL TEXT
Trends in Bacteremia in the Pre- and Post-Highly Active Antiretroviral Therapy Era Among HIV-Infected Children in the US Perinatal AIDS Collaborative Transmission Study (1986-2004)
Kapogiannis et al.
Pediatrics 2008;121:e1229-e1239.
ABSTRACT
| FULL TEXT
Pneumococcal Bacteremia in the Era of Potent Combination Antiretroviral Therapy
AIDS Clin Care 2005;2005:1-1.
FULL TEXT
|
